Trading Statement

RNS Number : 2488U

Omega Diagnostics Group PLC

13 October 2010

 



13 October 2010                                                                                                                      AIM: ODX 

Omega Diagnostics Group Plc

("Omega")

Trading Update

Omega, the AIM listed medical diagnostics company announces the following trading update for the six months to 30 September 2010 in advance of releasing its interim results on 26 November 2010.

Trading remains in line with management expectations with turnover approximately 15% ahead of the comparative period last year at £3.3 million (2009: £2.87 million). Sales of Genarrayt™ systems and Food Detective™ kits have grown strongly.  

Genarrayt™

Sales of Genarrayt™ kits and instrument packages have increased substantially in the period by approximately 72% to £761k (2009: £443k).  A further 22 system installations have occurred during this period in Brazil, Hungary, India, Israel, Italy, Malaysia, Syria, Thailand, Turkey and UAE bringing the total installed base around the world to approximately 80 systems since launch.  We are seeing increased traction of reagent sales from these installations.  Reagent sales alone were £632k (2009: £376k) in the period and we expect further progress in sales of reagent kits in the second half following this year's new system installations.

Food Detective™

Sales of the macroarray-based Food Detective™ have continued to perform well with volume growth particularly in the Middle East and Far East. Overall, sales of 19,225 kits have been achieved in the first half of this year (2009: 14,957 kits) providing revenues of £369k (2009: £348k). Volume growth has outstripped revenue growth due to the supply of bulk components to a customer in China who then assembles the kits locally. Food Detective™ is now available in over 40 countries.

The continued growth of both of these products in the second half of the year will be key.  The Directors remain confident in the Group's growth prospects and trading remains in line with management expectations.  Alongside the Group's organic growth we have continued to investigate acquisition opportunities.

Further enquiries:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive
Kieron Harbinson, Group Finance Director	www.omegadiagnostics.com
Cenkos Securities plc	Tel: [phone]
Ian Soanes Elizabeth Bowman
Walbrook PR Limited	Tel: [phone]
Paul McManus	Mob: [phone]
	[e-mail]

 

END

 

 

TSTFMMMGGZVGGZM